In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

ArQule, Inc.. Trade Record

NASDAQ:ARQL ArQule, Inc. stock gains 85.43% Exit Jun 15, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ARQL May 10, 2018, priceSeries
About ArQule, Inc.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The company's clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of Bruton's tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
93.84
Entry Date
May 10, 2018
Entry Price
2.72
Sell Date
Jun 15, 2018
Sell Price
5.04
Net Gain
85.43%
Hold Time
25 Trading Days